290 related articles for article (PubMed ID: 9972969)
1. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
Adams EM; Pucino F; Yarboro C; Hicks JE; Thornton B; McGarvey C; Sonies BC; Bartlett ML; Villalba ML; Fleisher T; Plotz PH
J Rheumatol; 1999 Feb; 26(2):352-60. PubMed ID: 9972969
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA
Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216
[TBL] [Abstract][Full Text] [Related]
3. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
4. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
Davis JC; Fessler BJ; Tassiulas IO; McInnes IB; Yarboro CH; Pillemer S; Wilder R; Fleisher TA; Klippel JH; Boumpas DT
J Rheumatol; 1998 Sep; 25(9):1694-704. PubMed ID: 9733448
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
Illei GG; Yarboro CH; Kuroiwa T; Schlimgen R; Austin HA; Tisdale JF; Chitkara P; Fleisher T; Klippel JH; Balow JE; Boumpas DT
Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
[TBL] [Abstract][Full Text] [Related]
6. [Dermatomyositis and polymyositis: clinical aspects and treatment].
Hachulla E
Ann Med Interne (Paris); 2001 Nov; 152(7):455-64. PubMed ID: 11965087
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis.
Lundberg I; Kratz AK; Alexanderson H; Patarroyo M
Arthritis Rheum; 2000 Feb; 43(2):336-48. PubMed ID: 10693873
[TBL] [Abstract][Full Text] [Related]
8. Rituximab as therapy for refractory polymyositis and dermatomyositis.
Noss EH; Hausner-Sypek DL; Weinblatt ME
J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for refractory polymyositis: an open-label prospective study.
Mok CC; Ho LY; To CH
J Rheumatol; 2007 Sep; 34(9):1864-8. PubMed ID: 17722224
[TBL] [Abstract][Full Text] [Related]
10. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.
Zong M; Loell I; Lindroos E; Nader GA; Alexanderson H; Hallengren CS; Borg K; Arnardottir S; McInnes IB; Lundberg IE
Ann Rheum Dis; 2012 Jun; 71(6):1055-63. PubMed ID: 22267334
[TBL] [Abstract][Full Text] [Related]
11. [The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis'].
Hoogendijk JE; Bijlsma JW; van Engelen BG; Lindeman E; van Royen-Kerkhof A; de Rie MA; de Visser M; Jennekens FG;
Ned Tijdschr Geneeskd; 2005 Sep; 149(38):2104-11. PubMed ID: 16201600
[TBL] [Abstract][Full Text] [Related]
12. Treatment of idiopathic inflammatory myopathies.
Amato AA; Griggs RC
Curr Opin Neurol; 2003 Oct; 16(5):569-75. PubMed ID: 14501840
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.
Qushmaq KA; Chalmers A; Esdaile JM
J Rheumatol; 2000 Dec; 27(12):2855-9. PubMed ID: 11128676
[TBL] [Abstract][Full Text] [Related]
14. Strength in polymyositis and dermatomyositis: best outcome in patients treated early.
Fafalak RG; Peterson MG; Kagen LJ
J Rheumatol; 1994 Apr; 21(4):643-8. PubMed ID: 8035387
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in the treatment of dermatomyositis: an open-label pilot study.
Levine TD
Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
[TBL] [Abstract][Full Text] [Related]
19. [Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins].
Chérin P; Herson S
Ann Med Interne (Paris); 1993; 144(8):521-5. PubMed ID: 8179241
[TBL] [Abstract][Full Text] [Related]
20. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.
Hengstman GJ; De Bleecker JL; Feist E; Vissing J; Denton CP; Manoussakis MN; Slott Jensen H; van Engelen BG; van den Hoogen FH
Eur Neurol; 2008; 59(3-4):159-63. PubMed ID: 18230873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]